Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Day One Biopharmaceuticals (DAWN) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $103.4 million.

  • Day One Biopharmaceuticals' Shares Outstanding (Diluted Average) rose 664.71% to $103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.4 million, marking a year-over-year increase of 664.71%. This contributed to the annual value of $93.2 million for FY2024, which is 1687.44% up from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Shares Outstanding (Diluted Average) stood at $103.4 million, which was up 664.71% from $103.1 million recorded in Q2 2025.
  • Over the past 5 years, Day One Biopharmaceuticals' Shares Outstanding (Diluted Average) peaked at $103.4 million during Q3 2025, and registered a low of $58.4 million during Q1 2022.
  • Over the past 4 years, Day One Biopharmaceuticals' median Shares Outstanding (Diluted Average) value was $86.0 million (recorded in 2023), while the average stood at $82.8 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first soared by 2337.76% in 2023, then skyrocketed by 664.71% in 2025.
  • Day One Biopharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $65.5 million in 2022, then increased by 21.85% to $79.8 million in 2023, then increased by 16.87% to $93.2 million in 2024, then rose by 10.88% to $103.4 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $103.4 million for Q3 2025, versus $103.1 million for Q2 2025 and $102.7 million for Q1 2025.